

## Press Release

### **Restructuring of Operations in Japan**

- *Restructuring Astellas Pharma Inc. and group companies in Japan, and offering early retirement incentive program* -

TOKYO, May 22, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced restructuring of operations in Japan and introduction of the early retirement incentive program.

To realize “Strategic Plan 2018” which was announced today, Astellas focus on building and optimizing its organizational capabilities and continue pursuing Operational Excellence. Accordingly, Astellas will restructure all operations, including R&D and Sales & Marketing, and its group companies in Japan.

- Discontinue all activities in Astellas Research Technologies Co., Ltd. (“ART”) and Astellas Marketing and Sales Support Co., Ltd. (“AES”) by the end of fiscal year 2018, ending March 31, 2019 (“FY2018”).
- Discontinue all operations of Astellas Learning Institute Co., Ltd. (“ALI”) except its green-supply supporting operations by the end of FY2018
- Divest Astellas Analytical Science Laboratories Co., Ltd. to Eurofins Pharma Services LUX Holding Sarl (planned closing: within FY2018)

With these restructuring efforts, Astellas is introducing an early retirement incentive program in FY2018 for employees of Astellas, AES, ART and ALI (estimated applicants to the program: 600).

#### **About Astellas**

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <https://www.astellas.com/en>

#### **Cautionary Notes**

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively,

(v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

---

**Contacts for inquiries or additional information:**

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473